224 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1221)
- Addiction (16)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (18)
- Bone & Muscle (10)
- Cancer (102)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (48)
- Insomnia (3)
- Kidney Disease (12)
- Liver Disease (52)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (126)
- Nutrition (5)
- Obesity (9)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (98)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (45)
- Urology (3)
- Vascular Conditions (10)
Displaying 1 - 18 of 18
Condition: Addiction / Opioids
Investigator: Felipe Castillo, Md
Status: Currently Recruiting
Looking for participants aged 18 to 55 who have trouble with heroin or other opiates to participate in a month-long research study at Columbia University Irving Medical Center evaluating the relationship between brain tasks and memory.
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Kiyohito Iigaya, PhD
Status: Currently Recruiting
Our lab is conducting brain imaging research studies investigating people's behavior. We are looking for people between the ages of 18 and 65 to be study participants. As a schizophrenia study participant, you will be asked to complete a set of self-report questionnaires probing personality traits. You will also complete a number of computer-based…
Condition: Addiction / Opioids
Investigator: Dana Sacco, MD
Status: Currently Recruiting
The purpose of this research study is to evaluate how commonly drug overdoses in our community involve fentanyl and xylazine. We know that often drugs such as heroin, oxycontin, and even cocaine and methamphetamine, actually contain these additives, even though the person buying the drugs is not aware.
Condition: Addiction / Opioids
Investigator: Rachel Luba, PhD
Status: Currently Recruiting
Columbia University Medical Center is recruiting individuals ages 18-65 who are seeking treatment for opioid use disorder to participate in a research treatment study. For your participation, you'll receive treatment with buprenorphine (either sublingual or injectable) at no cost. Participants will complete an overnight inpatient stay to start…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Guillermo Horga, MD, PhD
Status: Currently Recruiting
In this study, we are trying to learn more about the symptoms of psychosis, specifically to learn how alterations in the brain may produce certain experiences (including voice hearing or auditory hallucinations) that are common in people with psychosis or schizophrenia. The study involves clinical interviews, computer tests, and magnetic resonance imaging (…
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Have an Opioid Use Disorder? We need your help for an inpatient clinical research study! Help the New York State Psychiatric Institute research better treatment options for those with opioid use disorder.You could earn up to $12,017.00.You must meet the following criteria: - Age 18 -59 years old- Have opioid use disorder- Be currently taking an oral daily…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Gaurav Patel, MD, PhD
Status: Closed
Our lab is conducting a series of research studies that investigate how specific brain regions are related to functioning in work, school, and in other social situations. As a study participant, you will be asked to complete clinical and neuropsychological assessments, an eye-tracking task, and a non-invasive MRI scan. Study participants earn between $15-50…
Condition: Addiction / Opioids
Investigator: Frances Levin, MD
Status: Closed
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Guillermo Horga, MD, PhD
Status: Closed
In this study, we are trying to learn more about the symptoms of schizophrenia, specifically to learn how abnormalities in the brain may produce certain experiences that are common in patients with schizophrenia. The study involves clinical interviews, clinical chart review, computer tests, and magnetic resonance imaging (MRI) scans.
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in…
Study of VX15/2508 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Condition: Cancer / Solid Tumors
Investigator: Luca Szalontay, MD
Status: Closed
This is a Phase 1/2 multicenter study of VX15/2503 in pediatric patients and young adults with solid tumors which have come back or have not responded to standard therapy. The study treatment is considered experimental because VX15/2503 is not approved by the United States (US) Food and drug Administration (FDA) for treating pediatric patients and young…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Jeffrey Lieberman, MD
Status: Closed
This study plans to learn more about an investigational new drug called lumateperone tosylate (ITI-007) and may help us find new types of treatment for schizophrenia and schizoaffective disorder.
Condition: Addiction / Opioids
Investigator: Mina Rizk, MD
Status: Closed
This research study uses MRI scans to compare the effect of two medications on suicidal thoughts and brain activity in people who have opioid use disorder. We hope to develop a better understanding of how well these two medications help depression and suicidal thoughts. You may qualify if you have opioid use disorder and suicidal thoughts. Participation…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Joshua Kantrowitz, Md
Status: Closed
The purpose of this study is to determine whether the brain wave patterns are improved after administration of CVN058 compared to placebo in subjects with schizophrenia. The study uses electroencephalography (EEG) to measure naturally occurring brain waves as you listen to recorded sounds.
Condition: Addiction / Opioids
Investigator: Sandra Comer, PhD
Status: Closed
Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Joshua Kantrowitz, Md
Status: Closed
The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.